Tags

Type your tag names separated by a space and hit enter

[Pharmacokinetics of hylotelephin in Beagle dogs].
Yao Xue Xue Bao. 2006 Jul; 41(7):680-3.YX

Abstract

AIM

To investigate the pharmacokinetics of hylotelephin in Beagle dogs and obtain the main pharmacokinetic parameters.

METHODS

An HPLC method with UV detection was developed to study the pharmacokinetics of hylotelephin in dogs by joining an internal standard (anthracene). Benzoyl chloride was used to the pre-column derivatization of hylotelephin and methanol-water (64:36) was used as the mobile phase. According to the 3P97 pharmacokinetic program, the main parameters were calculated.

RESULTS

The hylotelephin pharmacokinetics conforms to a two-compartment open model after a single iv dose of hylotelephin 10.6 or 21.3 mg x kg(-1) in Beagle dogs. The parameters of two groups were as follows: T(1/2) alpha were 2.3 and 2.1 min, T(1/2) beta were 1.9 and 2.0 h, K12 were 0. 12 and 0.11 min, K21 were 0.17 and 0.21 min, K10 were 0.011 and 0.0094 min, Vc were 0.54 and 0.54 L x kg(-1), AUC were 1.8 and 4.1 g x min x L(-1), CL were 0.0048 and 0.0056 L x kg(-1) x min(-1), MRT were 2.10 and 2.4 h, respectively.

CONCLUSION

The pharmacokinetics of hylotelephin after iv administration showed a rapid distribution and elimination process in Beagle dogs and was of first order kinetics.

Authors+Show Affiliations

Department of Pharmacology, Chongqing University of Medical Sciences, Chongqing 400016, China. liuyingjbh@yahoo.com.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

17007365

Citation

Liu, Ying-ju, et al. "[Pharmacokinetics of Hylotelephin in Beagle Dogs]." Yao Xue Xue Bao = Acta Pharmaceutica Sinica, vol. 41, no. 7, 2006, pp. 680-3.
Liu YJ, Shang JC, Gao LJ, et al. [Pharmacokinetics of hylotelephin in Beagle dogs]. Yao Xue Xue Bao. 2006;41(7):680-3.
Liu, Y. J., Shang, J. C., Gao, L. J., He, Y. N., Zhou, L. P., & Mu, Z. D. (2006). [Pharmacokinetics of hylotelephin in Beagle dogs]. Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 41(7), 680-3.
Liu YJ, et al. [Pharmacokinetics of Hylotelephin in Beagle Dogs]. Yao Xue Xue Bao. 2006;41(7):680-3. PubMed PMID: 17007365.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacokinetics of hylotelephin in Beagle dogs]. AU - Liu,Ying-ju, AU - Shang,Jing-chuan, AU - Gao,Li-jia, AU - He,Ying-na, AU - Zhou,Li-ping, AU - Mu,Zhao-de, PY - 2006/9/30/pubmed PY - 2008/2/12/medline PY - 2006/9/30/entrez SP - 680 EP - 3 JF - Yao xue xue bao = Acta pharmaceutica Sinica JO - Yao Xue Xue Bao VL - 41 IS - 7 N2 - AIM: To investigate the pharmacokinetics of hylotelephin in Beagle dogs and obtain the main pharmacokinetic parameters. METHODS: An HPLC method with UV detection was developed to study the pharmacokinetics of hylotelephin in dogs by joining an internal standard (anthracene). Benzoyl chloride was used to the pre-column derivatization of hylotelephin and methanol-water (64:36) was used as the mobile phase. According to the 3P97 pharmacokinetic program, the main parameters were calculated. RESULTS: The hylotelephin pharmacokinetics conforms to a two-compartment open model after a single iv dose of hylotelephin 10.6 or 21.3 mg x kg(-1) in Beagle dogs. The parameters of two groups were as follows: T(1/2) alpha were 2.3 and 2.1 min, T(1/2) beta were 1.9 and 2.0 h, K12 were 0. 12 and 0.11 min, K21 were 0.17 and 0.21 min, K10 were 0.011 and 0.0094 min, Vc were 0.54 and 0.54 L x kg(-1), AUC were 1.8 and 4.1 g x min x L(-1), CL were 0.0048 and 0.0056 L x kg(-1) x min(-1), MRT were 2.10 and 2.4 h, respectively. CONCLUSION: The pharmacokinetics of hylotelephin after iv administration showed a rapid distribution and elimination process in Beagle dogs and was of first order kinetics. SN - 0513-4870 UR - https://www.unboundmedicine.com/medline/citation/17007365/[Pharmacokinetics_of_hylotelephin_in_Beagle_dogs]_ L2 - https://antibodies.cancer.gov/detail/CPTC-KRT+Group+A-1 DB - PRIME DP - Unbound Medicine ER -